Canagliflozin study for dialysis patients
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a diabetes medication called canagliflozin in people who receive dialysis treatment for kidney disease. Researchers want to see if it's safe and how it works in patients whose kidneys no longer function on their own.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been on hemodialysis (kidney filtration treatment) for more than 3 months
- You are at least 18 years old
- You are willing and able to provide informed consent (understand and agree to participate)
- If you are a woman who can become pregnant, you must use reliable contraception during the study
- You do not have a history of allergic reactions to canagliflozin or similar SGLT2 inhibitor medications
- You have not had significant gastrointestinal surgery, recent stomach ulcers, pancreas problems, or serious liver disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if canagliflozin, a diabetes medication, can help people with very advanced kidney disease or who recently started dialysis. It uses MRI scans to see how the drug affects the heart and kidneys.
This Phase 3 trial studies the safety of an SGLT2 inhibitor (a diabetes medication that can affect kidney fluid handling) in people on peritoneal dialysis. The goal is to see how the treatment works in your type of dialysis and whether it causes any problems.
This trial tests if canagliflozin, a diabetes medicine, helps remove extra fluid and reduce scarring in people on peritoneal dialysis (home-based dialysis). It may improve your dialysis results and protect your belly lining.
This study tests whether the medicine empagliflozin is safe and helpful for adults who are on regular hemodialysis and still make a small amount of urine. The goal is to see if it can improve health outcomes while tracking side effects closely.
This study tests whether dapagliflozin can improve kidney and heart-related outcomes in people with severe chronic kidney disease (CKD). You would take the study medicine (or a comparison treatment) and be followed to see how your kidneys and heart do over time.
This study tests whether a medicine called an SGLT2 inhibitor (which lowers blood sugar and helps the kidneys) can improve outcomes for people with acute heart failure and kidney problems. Participation involves taking the study drug or a placebo for a short time.
Hear when a new Dialysis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.